HRP20141008T1 - Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima - Google Patents

Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima Download PDF

Info

Publication number
HRP20141008T1
HRP20141008T1 HRP20141008AT HRP20141008T HRP20141008T1 HR P20141008 T1 HRP20141008 T1 HR P20141008T1 HR P20141008A T HRP20141008A T HR P20141008AT HR P20141008 T HRP20141008 T HR P20141008T HR P20141008 T1 HRP20141008 T1 HR P20141008T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
dosage form
pharmaceutically acceptable
active pharmaceutical
pharmaceutical
Prior art date
Application number
HRP20141008AT
Other languages
English (en)
Croatian (hr)
Inventor
Sandra Blundell
Panagiotis Keramidas
Brett Antony Mooney
Todd James Rutherford
Original Assignee
Alphapharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007900682A external-priority patent/AU2007900682A0/en
Application filed by Alphapharm Pty Ltd filed Critical Alphapharm Pty Ltd
Publication of HRP20141008T1 publication Critical patent/HRP20141008T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20141008AT 2007-02-09 2008-02-11 Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima HRP20141008T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007900682A AU2007900682A0 (en) 2007-02-09 Novel Formulation
PCT/AU2008/000169 WO2008095263A1 (en) 2007-02-09 2008-02-11 A dosage form containing two or more active pharmaceutical ingredients in different physical forms

Publications (1)

Publication Number Publication Date
HRP20141008T1 true HRP20141008T1 (hr) 2015-01-02

Family

ID=39681201

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20141008AT HRP20141008T1 (hr) 2007-02-09 2008-02-11 Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima

Country Status (15)

Country Link
US (1) US9095519B2 (enExample)
EP (1) EP2120878B1 (enExample)
JP (1) JP5467870B2 (enExample)
CN (1) CN101674811B (enExample)
AU (1) AU2008213744B2 (enExample)
CA (1) CA2677623C (enExample)
CY (1) CY1115652T1 (enExample)
DK (1) DK2120878T3 (enExample)
ES (1) ES2522297T3 (enExample)
HR (1) HRP20141008T1 (enExample)
NZ (1) NZ599031A (enExample)
PL (1) PL2120878T3 (enExample)
PT (1) PT2120878E (enExample)
SI (1) SI2120878T1 (enExample)
WO (1) WO2008095263A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100189797A1 (en) * 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2184055A1 (en) * 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
CN101780078B (zh) * 2010-02-10 2012-02-29 威特(湖南)药业有限公司 替米沙坦和氨氯地平复方制剂及其制备方法
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
PL2857014T3 (pl) * 2010-05-06 2016-12-30 Kompozycja farmaceutyczna zawierająca aspirynę i bisoprolol
CN102247366B (zh) * 2010-05-18 2015-04-15 广州白云山制药股份有限公司广州白云山制药总厂 包括依那普利和非洛地平的药物组合物缓释制剂
CN102028670A (zh) * 2010-09-06 2011-04-27 邓俐丽 一种包含替米沙坦和钙离子通道拮抗剂的复方胶囊剂
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
US9907789B2 (en) 2011-10-21 2018-03-06 Takeda Pharmaceutical Company Limited Sustained-release preparation
EP2793866B2 (en) 2011-12-21 2023-10-25 Elanco Tiergesundheit AG Bilayer tablet comprising benazepril hydrochloride and pimobendan
CN103169704A (zh) * 2011-12-26 2013-06-26 上海复星医药产业发展有限公司 烟酸和辛伐他汀复方缓释胶囊制剂及其制备方法
EP2814465B1 (en) 2012-02-17 2019-07-03 Egis Gyógyszergyár Zrt. Pharmaceutical formulation having improved stability
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CN102670630B (zh) * 2012-05-23 2013-11-27 重庆康刻尔制药有限公司 一种缬沙坦与氢氯噻嗪药物组合物胶囊剂及其制备方法
WO2014033077A1 (en) * 2012-08-28 2014-03-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
HUP1300496A2 (hu) 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stabil kombinációs gyógyszerkészítmény
CN103462903B (zh) * 2013-08-26 2016-06-22 中国人民解放军第150中心医院 一种盐酸吡格列酮缓释微丸制剂的制备工艺
US9566248B2 (en) * 2013-09-13 2017-02-14 R.P. Scherer Technologies, Llc Encased-pellet tablets
HU231036B1 (hu) * 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény
WO2015073573A1 (en) * 2013-11-14 2015-05-21 Jacobs Michael M Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
CN104382896A (zh) * 2014-11-04 2015-03-04 万全万特制药江苏有限公司 含有依折麦布和辛伐他汀的药物组合物
MA44212A (fr) * 2015-05-26 2018-12-26 Isa Odidi Prégabaline à libération prolongée contrôlée
WO2017023833A1 (en) * 2015-08-01 2017-02-09 Petti Stephen J Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
JP6831645B2 (ja) * 2016-06-14 2021-02-17 エルメッド株式会社 ガランタミン含有医薬組成物、医薬組成物におけるガランタミンの安定化方法、及びガランタミンの安定化剤
CN110913843B (zh) 2017-07-17 2022-09-13 伊莱利利公司 药物组合物
KR102500643B1 (ko) * 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
CN111388480B (zh) * 2020-03-26 2022-05-31 江苏长泰药业有限公司 一种奥氮平盐酸氟西汀复方制剂及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507276A (en) 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
ATE197900T1 (de) 1996-08-15 2000-12-15 Losan Pharma Gmbh Gut schluckbare orale arzneiform
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
JP2002516282A (ja) * 1998-05-22 2002-06-04 イーライ・リリー・アンド・カンパニー 難治性鬱病の処置のための組合せ治療
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
ID29021A (id) * 1998-12-24 2001-07-26 Janssen Pharmaceutica Nv Komposisi galantamina pelepasan terkontrol
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
MXPA03006217A (es) 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
DE50113344D1 (de) * 2001-01-31 2008-01-17 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CN1642524B (zh) * 2002-03-12 2011-05-18 微计量治疗公司 通过吸入部位特异性递送联合施用的药物
US6690577B2 (en) * 2002-07-02 2004-02-10 Hewlett-Packard Development Company, L.P. Air guide
DE60322091D1 (de) 2002-10-25 2008-08-21 Labopharm Inc Zubereitungen mit kontrollierter freisetzung
US7332183B2 (en) 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
WO2004062552A2 (en) * 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
EP2112920B1 (en) * 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1663174A1 (en) * 2003-08-05 2006-06-07 Galephar M/F Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent
JP4897483B2 (ja) * 2003-09-03 2012-03-14 ファルマトン ソシエテ アノニム 異なる放出プロフィールを有する活性物質ぺレット含有カプセル
ES2326251B1 (es) * 2005-06-12 2010-07-08 Elan Pharma International Limited Composiciones de ticlopidina de liberacion modificada.

Also Published As

Publication number Publication date
DK2120878T3 (da) 2014-11-03
EP2120878A1 (en) 2009-11-25
CA2677623A1 (en) 2008-08-14
EP2120878A4 (en) 2013-05-08
CN101674811B (zh) 2015-08-19
WO2008095263A1 (en) 2008-08-14
CN101674811A (zh) 2010-03-17
US9095519B2 (en) 2015-08-04
CA2677623C (en) 2015-04-07
SI2120878T1 (sl) 2014-12-31
PT2120878E (pt) 2014-11-05
JP2010518028A (ja) 2010-05-27
ES2522297T3 (es) 2014-11-14
JP5467870B2 (ja) 2014-04-09
AU2008213744A1 (en) 2008-08-14
CY1115652T1 (el) 2017-01-25
US20100092549A1 (en) 2010-04-15
AU2008213744B2 (en) 2013-12-05
NZ599031A (en) 2013-11-29
PL2120878T3 (pl) 2015-01-30
EP2120878B1 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
HRP20141008T1 (hr) Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima
HRP20210618T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
JP2020059755A5 (enExample)
ES2614179T3 (es) Uso de levodopa, carbidopa y entacapona para el tratamiento de la enfermedad de Parkinson
JP2015205922A5 (enExample)
HRP20180387T1 (hr) Oralne formulacije deferasiroksa
HRP20250561T1 (hr) Formulacija valbenazina visoke doze i pripravci, postupci i pribor povezani s njima
HRP20240564T1 (hr) Novi farmaceutski sastav
JP2017019858A5 (enExample)
PH12015502134B1 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
HRP20170677T1 (hr) Farmaceutski sastav za kontrolirano otpuštanje koji sadrži ester fumarne kiseline
US20150216849A1 (en) Donepezil compositions and methods of treating alzheimers disease
HRP20090341T1 (hr) Mekane kapsule koje sadrže palonosetron hidroksiklorid s poboljšanom stabilnosti i bioraspoloživosti
HRP20241461T1 (hr) Aprocitentan za uporabu u liječenju hipertenzije i povezanih bolesti u kombinaciji s valsartanom
HRP20170864T1 (hr) Čvrsti dozni oblici s kontroliranim oslobađanjem
BR112015028644A2 (pt) composições de cenicriviroc e métodos de criação e uso do mesmo
CN106389381A (zh) 金刚烷胺组合物及其使用方法
JP2010527347A5 (enExample)
Zhang et al. Preparation and in vitro–in vivo evaluation of sustained-release matrix pellets of capsaicin to enhance the oral bioavailability
RU2014140177A (ru) Фармацевтические антиретровирусные композиции
AU2007239057A1 (en) Low flush niacin formulation
JP2007509891A5 (enExample)
HRP20171743T1 (hr) Sastavi i postupci za savladavanje otpornosti na tramadol
JP2018527305A5 (enExample)
JP2013544290A5 (enExample)